Shares of Ionis Pharmaceuticals IONS remained unaffected after the company reported Q4 results.
Quarterly Results
Earnings per share fell 39.10% over the past year to $0.81, which beat the estimate of $0.28.
Revenue of $290,000,000 decreased by 41.30% from the same period last year, which beat the estimate of $274,480,000.
Looking Ahead
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
How To Listen To The Conference Call
Date: Feb 24, 2021
Time: 09:00 AM
ET Webcast URL: https://www.webcaster4.com/Webcast/Page/952/39530
Price Action
Company's 52-week high was at $64.37
52-week low: $39.32
Price action over last quarter: Up 15.05%
Company Description
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Ionis' broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy. Ionis subsequently brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
